Vishnu Chemicals Limited, a leading global player in the manufacturing of speciality chemicals, has reported Q2 FY25 consolidated revenue of Rs. 343.8 crore, an increase of 12.2% vis-a-vis Q2 FY24. 

Consolidated EBITDA Margin stood at 13.1% in Q2 FY25 compared to 14.9% in Q2 FY24.

On a consolidated basis, the domestic to exports sales mix was 57:43 driven by a stronger demand environment in the domestic market. The company remains cautiously optimistic about the recovery in the export market, which continues to face challenges due to geo-political and inflationary pressures.

Consolidated PAT decreased by 5% Y-o-Y and Standalone PAT declined by 28.7% Y-o-Y primarily due to the rising input and freight costs along with one-time administrative expenses associated with acquisition of Jayanshree Pharma made during the quarter.

Krishna Murthy Ch., CMD, Vishnu Chemicals Limited said, “In FY25, we have entered into two definitive agreements to acquire businesses that align well with our portfolio, enhancing both our operational capabilities and resilience to external pressures. Our strong, cash-rich balance sheet, coupled with a low-debt profile, continues to provide us with the flexibility to invest strategically in assets that drive long-term value for our shareholders.”

“We are pleased with the progress we have made in executing our enterprise strategy in a tough business environment. We continue to balance our long-term growth objectives with the realities of the current market conditions, positioning ourselves for sustained success as we navigate through these uncertain times,” said Siddartha Ch., JMD, Vishnu Chemicals Limited.